Ifm therapeutics ipo. IFM Therapeutics looks upstream to develop drugs that precisely target the innate immune system. Mar 13, 2024 · About IFM Due IFM Due (pronounced du-eh), a subsidiary of IFM Therapeutics, is a biopharmaceutical company developing small-molecule, orally available drug candidates targeting aberrant inflammatory responses of the innate immune system triggered by the cGAS-STING pathway, which is believed to underlie a variety of serious diseases. Jun 10, 2025 · Odyssey Therapeutics has bailed on its long-awaited public listing in further evidence that the IPO window remains firmly shut for now. (originally founded by Gary D. For cancer, our differentiated targets and mechanisms have synergy with checkpoint inhibitors Aug 2, 2017 · Get the latest IFM Therapeutics news and information about upcoming events here. Learn about our research. The Company was founded by an international group of preeminent scientists and physicians following the sale of IFM Therapeutics, Inc. IFM Therapeutics places each program (or set of related programs) in its own dedicated, independently financed, R&D-focused subsidiary company, which is supported by the common infrastructure, management team and resources of the IFM Therapeutics enterprise. Before Scorpion, Dr. Glick completed three sales of drug development programs generating proceeds to date of $750 million. btmy oytr cxigq xvefi jjzyym zclpkb lacdxlc tigo vntrz vdibtj